Ebrahimi Hedyeh, Naderian Mohammadreza, Sohrabpour Amir Ali
Liver and Pancreaticobiliary Diseases Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Assistant Professor, Liver and Pancreaticobiliary Diseases Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Middle East J Dig Dis. 2016 Jul;8(3):166-178. doi: 10.15171/mejdd.2016.29.
Liver fibrosis is a potentially reversible response to hepatic insults, triggered by different chronic diseases most importantly viral hepatitis, alcoholic, and nonalcoholic fatty liver disease. In the course of the chronic liver disease, hepatic fibrogenesis may develop, which is attributed to various types of cells, molecules, and pathways. Activated hepatic stellate cell (HSC), the primary source of extracellular matrix (ECM), is fundamental in pathophysiology of fibrogenesis, and thus is the most attractable target for reversing liver fibrosis. Although, liver biopsy has long been considered as the gold standard for diagnosis and staging of hepatic fibrosis, assessing progression and regression by biopsy is hampered by its limitations. We provide recent views on noninvasive approaches including serum biomarkers and radiologic techniques.
肝纤维化是对肝脏损伤的一种潜在可逆反应,由不同的慢性疾病引发,其中最重要的是病毒性肝炎、酒精性肝病和非酒精性脂肪性肝病。在慢性肝病过程中,可能会发生肝纤维化,这归因于多种类型的细胞、分子和途径。活化的肝星状细胞(HSC)是细胞外基质(ECM)的主要来源,在肝纤维化的病理生理学中起关键作用,因此是逆转肝纤维化最具吸引力的靶点。尽管长期以来肝活检一直被视为肝纤维化诊断和分期的金标准,但活检评估进展和消退存在局限性。我们提供了关于包括血清生物标志物和放射学技术在内的非侵入性方法的最新观点。